Paclitaxel Injection 260mg
PACLIEVA 260 MG (Paclitaxel Injection 260 mg) is a prescription anticancer medicine containing Paclitaxel 260 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately leads to cancer cell death. Due to its established efficacy, Paclitaxel has become an important component of modern oncology treatment protocols worldwide.
PACLIEVA 260 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 260 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 260 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, PACLIEVA 260 MG remains an important medicine in modern cancer management.
View Details
Paclitaxel Injection 100 mg
PACLIEVA 100 MG (Paclitaxel Injection 100 mg) is a prescription anticancer medicine containing Paclitaxel 100 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by inhibiting cancer cell division and slowing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately causes cancer cell death. Due to its established efficacy, Paclitaxel has become an important component of modern oncology treatment protocols worldwide.
PACLIEVA 100 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used as a single-agent therapy or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The 100 mg strength provides flexibility for individualized dosing and combination chemotherapy regimens based on patient-specific clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 100 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 100 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require regular monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and proven effectiveness, PACLIEVA 100 MG remains an important medicine in modern cancer care.
View Details
Paclitaxel Injection 30 mg
PACLIEVA 30 MG (Paclitaxel Injection 30 mg) is a prescription anticancer medicine containing Paclitaxel 30 mg, a chemotherapy agent belonging to the Taxane class of anticancer drugs. Paclitaxel is widely used in the treatment of various cancers by interfering with cancer cell division and preventing tumor growth and spread.
Paclitaxel works by stabilizing microtubules within cancer cells, preventing their normal breakdown during cell division. This action disrupts mitosis, inhibits cancer cell replication, and ultimately causes cancer cell death. Due to its proven efficacy, Paclitaxel is a key component of many oncology treatment protocols worldwide.
PACLIEVA 30 MG is commonly prescribed for the treatment of breast cancer, ovarian cancer, non-small cell lung cancer (NSCLC), Kaposi’s sarcoma, and other advanced solid tumors. It may be used alone or in combination with other anticancer medicines depending on the patient's diagnosis and treatment plan.
The 30 mg strength provides flexibility for individualized dosing, dose adjustments, and combination chemotherapy regimens based on patient-specific clinical requirements.
The medicine is administered intravenously under the supervision of qualified healthcare professionals experienced in oncology treatment.
PACLIEVA 30 MG is commonly used for:
Breast Cancer
Ovarian Cancer
Non-Small Cell Lung Cancer (NSCLC)
Advanced Ovarian Cancer
Metastatic Breast Cancer
Kaposi’s Sarcoma
Advanced Solid Tumors
Combination Chemotherapy Programs
Oncology Treatment Protocols
Manufactured according to stringent pharmaceutical quality standards, PACLIEVA 30 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Paclitaxel therapy require routine monitoring of blood counts, liver function, and overall health status throughout treatment.
Due to its broad clinical applications and established effectiveness, PACLIEVA 30 MG remains an important medicine in modern cancer care.
View Details
Regorafenib Tablet BP 40mg
REGOLIEVA 40 MG (Regorafenib Tablets BP 40 mg) is a prescription anticancer medicine containing Regorafenib 40 mg, an oral multi-kinase inhibitor used in the treatment of certain advanced cancers. Regorafenib belongs to a class of medicines known as Targeted Therapy Agents, which work by blocking multiple protein kinases involved in tumor growth, cancer progression, and blood vessel formation.
Regorafenib inhibits various signaling pathways responsible for cancer cell proliferation and angiogenesis (formation of new blood vessels that supply tumors). By targeting these pathways, the medicine helps slow tumor growth and disease progression.
REGOLIEVA 40 MG is commonly prescribed for the treatment of metastatic colorectal cancer (mCRC), gastrointestinal stromal tumors (GIST) after failure of prior therapies, and hepatocellular carcinoma (HCC) in selected patients. It may also be used according to the oncologist's recommendation as part of specific cancer treatment protocols.
The medicine is administered orally and should be taken exactly as prescribed by a qualified healthcare professional experienced in oncology treatment.
REGOLIEVA 40 MG is commonly used for:
Metastatic Colorectal Cancer (mCRC)
Gastrointestinal Stromal Tumor (GIST)
Hepatocellular Carcinoma (HCC)
Advanced Solid Tumors
Targeted Cancer Therapy
Oncology Treatment Programs
Tumor Growth Control
Cancer Progression Management
Manufactured according to stringent pharmaceutical quality standards, REGOLIEVA 40 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Regorafenib therapy require regular monitoring of liver function, blood pressure, and overall health status throughout treatment.
Due to its targeted mechanism of action and proven clinical efficacy, REGOLIEVA 40 MG remains an important option in modern oncology care.
View Details
